Kaskela Law LLC Announces Stockholder Investigation of Apyx Medical Corp. (APYX) and Encourages Long-Term APYX Stockholders to Contact the Firm

Editorial & Advertiser Disclosure Global Banking And Finance Review is an independent publisher which offers News, information, Analysis, Opinion, Press Releases, Reviews, Research reports covering various economies, industries, products, services and companies. The content available on globalbankingandfinance.com is sourced by a mixture of different methods which is not limited to content produced and supplied by various staff writers, journalists, freelancers, individuals, organizations, companies, PR agencies etc. The information available on this website is purely for educational and informational purposes only. We cannot guarantee the accuracy or applicability of any of the information provided at globalbankingandfinance.com with respect to your individual or personal circumstances. Please seek professional advice from a qualified professional before making any financial decisions. Globalbankingandfinance.com also links to various third party websites and we cannot guarantee the accuracy or applicability of the information provided by third party websites.
Links from various articles on our site to third party websites are a mixture of non-sponsored links and sponsored links. Only a very small fraction of the links which point to external websites are affiliate links. Some of the links which you may click on our website may link to various products and services from our partners who may compensate us if you buy a service or product or fill a form or install an app. This will not incur additional cost to you. For avoidance of any doubts and to make it easier, you may consider any links to external websites as sponsored links. Please note that some of the services or products which we talk about carry a high level of risk and may not be suitable for everyone. These may be complex services or products and we request the readers to consider this purely from an educational standpoint. The information provided on this website is general in nature. Global Banking & Finance Review expressly disclaims any liability without any limitation which may arise directly or indirectly from the use of such information.

Kaskela Law LLC is investigating Apyx Medical Corporation (NASDAQ: APYX) (Apyx or the Company) on behalf of the Companys stockholders.

In September 2019, a securities fraud complaint was filed against Apyx in federal court on behalf of certain purchasers of Apyxs common stock. Among other things, the complaint alleged that Apyx violated the federal securities laws by making a series of materially false and misleading statements to investors between December 2018 and April 2019 concerning Apyxs business, operations, and prospects.

As detailed in the complaint, on December 21, 2018, Apyx announced that it had submitted a 510(k) application for regulatory clearance with the FDA for the use of J-Plasma (a patented helium-based plasma surgical product) for dermal resurfacing based on the results of a clinical study. Also on that day, Apyxs CEO stated: We were very pleased with the clinical results of this study and we are optimistic in receiving regulatory clearance for this differentiated technology in 2019.

However, on April 1, 2019, Apyx announced that it had withdrawn its application for regulatory clearance and disclosed that the study had failed to meet its primary efficacy endpoint. Additionally, the Company revealed that one of three investigational centers used in the study had deviated from protocol by prescribing a steroid to its patients. Following this news, shares of the Companys stock declined $2.49 per share, or nearly 36% in value, to close at $4.46 per share on April 2, 2019.

The investigation seeks to determine whether the members of Apyxs board of directors breached their fiduciary duties in connection with the above.

Current Apyx stockholders who purchased or acquired shares of the Companys stock prior to December 21, 2018 are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq.) at (484) 258 “ 1585, or via email at [email protected] or online at http://kaskelalaw.com/case/apyx-medical-corp/, to discuss this investigation and their legal rights and options.

Kaskela Law LLC represents investors in securities fraud, corporate governance, and merger & acquisition litigation. For additional information about Kaskela Law LLC please visit www.kaskelalaw.com. This notice may constitute attorney advertising in certain jurisdictions.

D. Seamus Kaskela, Esq.


(484) 258 – 1585

(888) 715 – 1740


[email protected]